ERS Genomics:
The global CRISPR/Cas9 licensing leader

Based on the Nobel Prize winning invention of Emmanuelle Charpentier and Jennifer Doudna, CRISPR/Cas9 has transformed gene editing. ERS licenses worldwide access to the essential CRISPR/Cas9 patent portfolio.

Dr. Emmanuelle Charpentier

ERS co-founder, patent co-owner, and 2020 Nobel Prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 50 granted patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.

Empowering the CRISPR/Cas9
platform globally

Non-exclusive licenses are available to companies for internal research and sale of products and services, in a wide range of fields.

Pharmaceutical & biotech
Agriculture & livestock
Industrial & synthetic biology
CRO, CMO & tools providers
Companion animal/ veterinary medicine